Towards liquid biopsy-based analysis of antitumour immunity

IF 94.6 1区医学 Q1 ONCOLOGY

Nature Reviews Clinical Oncology Pub Date : 2026-07-24 DOI:10.1038/s41571-026-01181-8

Klaus Pantel, Doryan Masmoudi, Catherine Alix-Panabières

{"title":"Towards liquid biopsy-based analysis of antitumour immunity","authors":"Klaus Pantel, Doryan Masmoudi, Catherine Alix-Panabières","doi":"10.1038/s41571-026-01181-8","DOIUrl":null,"url":null,"abstract":"Analysis of tissue biopsy samples is the gold-standard approach to cancer diagnosis and patient selection for biomarker-guided therapies. Although spatial analyses of tumour tissue can provide important insights into local antitumour immune responses, repeated tumour biopsy is invasive and rarely feasible for monitoring dynamic immune responses over time. Technical advances have enabled multimodal analyses of cells and cellular products in peripheral blood samples, which can be obtained easily and repeatedly over the course of the disease. These liquid biopsy-based approaches cannot provide spatial information on the tumour immune microenvironment and tumour-derived material can be highly diluted in the circulation, yet they offer a unique opportunity to monitor systemic immune dynamics, anticipate responses to immunotherapies and detect emerging resistance to treatment. Thus, blood-based analyses might complement tumour tissue analysis. In this Review, we discuss insights on systemic antitumour immune responses that can be gained through the analysis of tumour-derived biomarkers in peripheral blood and/or circulating immune cells. Advances in multimodal analyses of diverse cell types and cellular products present in the blood have presented opportunities to non-invasively and repeatedly assess systemic immune dynamics, predict and monitor responses to immunotherapies, and detect emerging resistance in patients with cancer. In this Review, the authors discuss various insights on systemic antitumour immune responses that can be gleaned through such liquid biopsy-based analysis of circulating tumour-derived biomarkers and/or immune cells and their implications for immunotherapy.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"23 10","pages":"766-791"},"PeriodicalIF":94.6000,"publicationDate":"2026-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41571-026-01181-8","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Analysis of tissue biopsy samples is the gold-standard approach to cancer diagnosis and patient selection for biomarker-guided therapies. Although spatial analyses of tumour tissue can provide important insights into local antitumour immune responses, repeated tumour biopsy is invasive and rarely feasible for monitoring dynamic immune responses over time. Technical advances have enabled multimodal analyses of cells and cellular products in peripheral blood samples, which can be obtained easily and repeatedly over the course of the disease. These liquid biopsy-based approaches cannot provide spatial information on the tumour immune microenvironment and tumour-derived material can be highly diluted in the circulation, yet they offer a unique opportunity to monitor systemic immune dynamics, anticipate responses to immunotherapies and detect emerging resistance to treatment. Thus, blood-based analyses might complement tumour tissue analysis. In this Review, we discuss insights on systemic antitumour immune responses that can be gained through the analysis of tumour-derived biomarkers in peripheral blood and/or circulating immune cells. Advances in multimodal analyses of diverse cell types and cellular products present in the blood have presented opportunities to non-invasively and repeatedly assess systemic immune dynamics, predict and monitor responses to immunotherapies, and detect emerging resistance in patients with cancer. In this Review, the authors discuss various insights on systemic antitumour immune responses that can be gleaned through such liquid biopsy-based analysis of circulating tumour-derived biomarkers and/or immune cells and their implications for immunotherapy.

查看原文本刊更多论文

基于液体活检的抗肿瘤免疫分析。

组织活检样本分析是癌症诊断和生物标志物引导疗法患者选择的金标准方法。尽管肿瘤组织的空间分析可以为局部抗肿瘤免疫反应提供重要的见解，但重复的肿瘤活检是侵入性的，并且很少可行，用于监测一段时间内的动态免疫反应。技术进步使外周血样本中的细胞和细胞产物的多模式分析成为可能，可以在疾病过程中轻松和重复地获得这些分析。这些基于液体活检的方法不能提供肿瘤免疫微环境的空间信息，肿瘤来源的物质在血液循环中可能被高度稀释，但它们提供了一个独特的机会来监测全身免疫动力学，预测对免疫疗法的反应，并检测对治疗的新耐药性。因此，基于血液的分析可能是对肿瘤组织分析的补充。在这篇综述中，我们讨论了通过分析外周血和/或循环免疫细胞中肿瘤来源的生物标志物可以获得的全身抗肿瘤免疫反应的见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.